| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/1874192400701010008 |
| P8608 | Fatcat ID | release_goyg2qqfuvctxp357x7g5ipmby |
| P932 | PMC publication ID | 2570568 |
| P698 | PubMed publication ID | 18949085 |
| P5875 | ResearchGate publication ID | 23410471 |
| P50 | author | Dimitri P Mikhailidis | Q62561943 |
| Efstathios D Pagourelias | Q89509499 | ||
| P2093 | author name string | Konstantinos Tziomalos | |
| Moses Elisaf | |||
| Asterios Karagiannis | |||
| Vasilios G Athyros | |||
| Anna I Kakafika | |||
| Athanasios A Papageorgiou | |||
| Savvas D Savvatianos | |||
| P2860 | cites work | Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction | Q28213597 |
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| Lipids, protein intake, and diabetic nephropathy. | Q33988932 | ||
| HDL and the inflammatory response induced by LDL-derived oxidized phospholipids | Q34220276 | ||
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| Early vascular benefits of statin therapy | Q35574104 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Cellular lipid metabolism and the role of lipids in progressive renal disease | Q35621071 | ||
| Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function | Q36032984 | ||
| Mechanisms of disease: proatherogenic HDL--an evolving field | Q36587579 | ||
| Hyperlipidemia and the progression of renal disease | Q39626276 | ||
| Focal and segmental glomerulosclerosis: analogies to atherosclerosis | Q39652278 | ||
| High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. | Q40437230 | ||
| Molecular physiology of reverse cholesterol transport | Q40526401 | ||
| Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease | Q41533607 | ||
| Effects of hypertension and dyslipidemia on the decline in renal function | Q41668265 | ||
| Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines | Q43629059 | ||
| Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion | Q43776883 | ||
| Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction | Q44088250 | ||
| Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | Q44118533 | ||
| Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury | Q44174624 | ||
| Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways | Q44249749 | ||
| Cholesterol and the risk of renal dysfunction in apparently healthy men. | Q44521397 | ||
| Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | Q44813339 | ||
| Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease | Q45113794 | ||
| Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease | Q46584977 | ||
| Cardiovascular disease and chronic renal disease: a new paradigm | Q47592629 | ||
| Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats | Q51626266 | ||
| High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. | Q54156669 | ||
| The role of lipids in progressive glomerular disease | Q68698615 | ||
| Early glomerular changes in rats with dietary-induced hypercholesterolemia | Q71878212 | ||
| Lovastatin retards the progression of established glomerular disease in obese Zucker rats | Q72809773 | ||
| Statins and renal function. Is the compound and dose making a difference? | Q79665672 | ||
| Statin treatment may be beneficial to both the kidneys and the heart | Q79771405 | ||
| Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin | Q79906376 | ||
| Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Ev | Q80335956 | ||
| The effect of cholesterol-lowering treatment on renal function | Q82614615 | ||
| P921 | main subject | heart disease | Q190805 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 8-14 | |
| P577 | publication date | 2007-07-28 | |
| P1433 | published in | Open Cardiovascular Medicine Journal | Q15817299 |
| P1476 | title | Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients | |
| P478 | volume | 1 |
| Q43595409 | Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. |
| Q37582058 | Coronary stent thrombosis in patients with chronic renal insufficiency. |
| Q35029623 | Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment |
| Q55396017 | Effect of cardiac rehabilitation on the renal function in chronic kidney disease - Analysis using serum cystatin-C based glomerular filtration rate. |
| Q37400405 | High-density lipoprotein cholesterol: current perspective for clinicians |
| Q37704388 | Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy |
| Q36310496 | Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters |
| Q34999753 | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
| Q35622817 | Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role? |
| Q38092812 | Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. |
| Q34567227 | The effects of tai chi on the renal and cardiac functions of patients with chronic kidney and cardiovascular diseases |
Search more.